AR053948A1 - Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente - Google Patents

Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente

Info

Publication number
AR053948A1
AR053948A1 ARP060102872A ARP060102872A AR053948A1 AR 053948 A1 AR053948 A1 AR 053948A1 AR P060102872 A ARP060102872 A AR P060102872A AR P060102872 A ARP060102872 A AR P060102872A AR 053948 A1 AR053948 A1 AR 053948A1
Authority
AR
Argentina
Prior art keywords
therapeutic antibody
diana
ancient
absence
independently
Prior art date
Application number
ARP060102872A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR053948A1 publication Critical patent/AR053948A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP060102872A 2005-07-06 2006-07-04 Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente AR053948A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
AR053948A1 true AR053948A1 (es) 2007-05-23

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102872A AR053948A1 (es) 2005-07-06 2006-07-04 Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente

Country Status (19)

Country Link
US (1) US20070009976A1 (enExample)
EP (2) EP2194380A3 (enExample)
JP (1) JP2008545145A (enExample)
KR (1) KR20080016939A (enExample)
AR (1) AR053948A1 (enExample)
AU (1) AU2006265275A1 (enExample)
BR (1) BRPI0612591A2 (enExample)
CA (1) CA2613187A1 (enExample)
CR (1) CR9635A (enExample)
EC (1) ECSP088081A (enExample)
IL (1) IL188317A0 (enExample)
MA (1) MA29730B1 (enExample)
MX (1) MX2008000277A (enExample)
MY (1) MY157955A (enExample)
NO (1) NO20076662L (enExample)
NZ (1) NZ564471A (enExample)
RU (1) RU2008103608A (enExample)
TW (1) TWI312864B (enExample)
WO (1) WO2007003420A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522444A (en) * 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CN101680897B (zh) 2007-03-02 2013-11-13 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2014004021A (es) 2011-10-14 2014-04-30 Genentech Inc Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
RS65871B1 (sr) 2015-05-30 2024-09-30 Hoffmann La Roche Postupci lečenja her2-pozitivnog prethodno nelečenog metastatskog karcinoma dojke
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
TWI729259B (zh) 2017-01-17 2021-06-01 美商建南德克公司 皮下her2 抗體調配物
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
IL129354A0 (en) 1996-10-18 2000-02-17 Genentech Inc Anti-ErbB2 antibodies
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)

Also Published As

Publication number Publication date
EP2194380A3 (en) 2010-07-14
EP2194380A2 (en) 2010-06-09
CA2613187A1 (en) 2007-01-11
US20070009976A1 (en) 2007-01-11
IL188317A0 (en) 2008-04-13
TW200741203A (en) 2007-11-01
MA29730B1 (fr) 2008-09-01
EP1902315A1 (en) 2008-03-26
RU2008103608A (ru) 2009-08-20
AU2006265275A1 (en) 2007-01-11
KR20080016939A (ko) 2008-02-22
NZ564471A (en) 2010-04-30
CR9635A (es) 2008-02-20
MY157955A (en) 2016-08-30
JP2008545145A (ja) 2008-12-11
TWI312864B (en) 2009-08-01
BRPI0612591A2 (pt) 2010-11-23
NO20076662L (no) 2008-04-03
WO2007003420A1 (en) 2007-01-11
MX2008000277A (es) 2008-03-24
ECSP088081A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
ECSP088081A (es) Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente
EP4603594A3 (en) Increasing spatial array resolution
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
CL2007001536A1 (es) Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
EP3877766A4 (en) DETECTION OF ANALYTES USING REGULATED IN VITRO TRANSCRIPTION
TW200801202A (en) Alpha-enolase specific antibody and method of use
MX2009012048A (es) Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato.
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
BR112018017336A2 (pt) método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão
PE20130526A1 (es) Componentes de la pared de celulas de levadura y deteccion de los mismos
MX2017010505A (es) Inmunoensayo homogeneo con compensacion para señal de fondo.
AR108771A1 (es) MÉTODO PARA LA DETECCIÓN DE UN ANTICUERPO IgM ESPECÍFICO PARA UN FLAVIVIRUS EN UNA MUESTRA
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
ES2527703B1 (es) Inmunosensor electroquímico para la determinación cuantitativa de la micotoxina fb1
CL2009001323A1 (es) Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc.
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
PL1991875T3 (pl) Test do wykrywania patologicznych prionów
GB201107557D0 (en) Method

Legal Events

Date Code Title Description
FA Abandonment or withdrawal